Holen Sie sich die Stockscreener-App
8.96
1.86%
-0.17
Handel nachbörslich:
8.96
Schlusskurs vom Vortag:
$9.13
Offen:
$9.02
24-Stunden-Volumen:
467.41K
Relative Volume:
0.47
Marktkapitalisierung:
$451.48M
Einnahmen:
$89.04M
Nettoeinkommen (Verlust:
$-241.08M
KGV:
-1.7034
EPS:
-5.26
Netto-Cashflow:
$-194.72M
1W Leistung:
+9.80%
1M Leistung:
+4.92%
6M Leistung:
+13.71%
1J Leistung:
-37.73%
1-Tages-Spanne:
$8.86
$9.22
1-Wochen-Bereich:
$8.14
$9.22
52-Wochen-Spanne:
$5.035
$15.36
Regenxbio Inc Stock (RGNX) Company Profile
Firmenname
Regenxbio Inc
Sektor
Branche
Telefon
240-552-8181
Adresse
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Vergleichen Sie RGNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
8.96 | 460.05M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-11 | Herabstufung | Goldman | Buy → Neutral |
| 2025-02-07 | Fortgesetzt | Raymond James | Outperform |
| 2024-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-06-07 | Eingeleitet | Goldman | Buy |
| 2024-03-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-08 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Fortgesetzt | Raymond James | Outperform |
| 2023-11-01 | Eingeleitet | Stifel | Buy |
| 2023-06-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-12-15 | Eingeleitet | Wedbush | Neutral |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-01-06 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-06-25 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-14 | Fortgesetzt | Raymond James | Outperform |
| 2019-06-05 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-25 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-11-08 | Bestätigt | BofA/Merrill | Neutral |
| 2018-08-08 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-07-23 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-05-09 | Bestätigt | Barclays | Overweight |
| 2018-04-09 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-03-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Eingeleitet | Mizuho | Neutral |
| 2017-11-09 | Fortgesetzt | Morgan Stanley | Overweight |
Alle ansehen
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
What drives REGENXBIO Inc. stock priceJaw-dropping returns - PrintWeekIndia
What institutions are buying REGENXBIO Inc. stock nowTriple returns potential - jammulinksnews.com
REGENXBIO Inc. (RGNX): A Bull Case Theory - Insider Monkey
What analysts say about REGENXBIO Inc. stockStrong return on investment - Autocar Professional
The Duchenne Gene Therapies Lining Up To Take Elevidys’ Place - insights.citeline.com
REGENXBIO Inc. Stock Analysis and ForecastExplosive trading opportunities - jammulinksnews.com
Is REGENXBIO Inc. a good long term investmentConsistently outstanding ROI - jammulinksnews.com
REGENXBIO Inc. (NASDAQ:RGNX) is largely controlled by institutional shareholders who own 67% of the company - Yahoo Finance
(RGNX) Technical Pivots with Risk Controls - news.stocktradersdaily.com
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
REGENXBIO’s gene therapy with CT domain shows improved muscle function in study By Investing.com - Investing.com South Africa
REGENXBIO’s gene therapy with CT domain shows improved muscle function in study - Investing.com
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy - WV News
Diabetic Retinopathy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | | Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics - Barchart.com
RBC Capital Remains a Buy on RegenXBio (RGNX) - The Globe and Mail
RBC Capital Maintains Regenxbio(RGNX.US) With Buy Rating, Cuts Target Price to $21 - 富途牛牛
Regenxbio (RGNX) Maintains Strong Outlook Amid Competitor Safety Concerns | RGNX Stock News - GuruFocus
REGENXBIO (RGNX) Prepares for Potential $4M Warrant Cash Influx - GuruFocus
Regenxbio (RGNX) Proposes Sale of Over 268,000 Shares | RGNX Stock News - GuruFocus
Regenxbio (RGNX) Maintains Buy Rating with $52 Price Target | RGNX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts - Benzinga
Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism - TipRanks
REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN
Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha
H.C. WAINWRIGHT MAINTAINS BUY RATING ON REGENXBIO STOCK AFTER POSITIVE TRIAL DATA - Investing.com Nigeria
Duchenne gene therapy interim trial outcomes "striking" - MarketScreener
Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update - BioPharma Dive
RegeNXBio shares fall, despite positive new data on RGX-202 - The Pharma Letter
REGENXBIO reports progress in Duchenne treatment trial By Investing.com - Investing.com South Africa
Regenxbio’s Duchenne gene therapy data positive as shares falter - BioWorld MedTech
New Regenxbio DMD Data Support Gene Therapy Accelerated Approval - insights.citeline.com
Stifel reiterates Buy rating on Regenxbio stock after trial data By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Regenxbio stock after trial data - Investing.com Australia
Finanzdaten der Regenxbio Inc-Aktie (RGNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):